Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is a global healthcare company headquartered in Alameda, California, specializing in innovative interventional therapies. The company is renowned for developing and marketing medical devices aimed at treating complex medical conditions with significant unmet clinical needs. Penumbra's product portfolio includes neurovascular and peripheral vascular devices, which are primarily used by specialist physicians in hospitals.
Penumbra's neurovascular product line, which generates the majority of the company's revenue, includes technologies for neurovascular access, ischemic stroke treatment, neurovascular embolization, and neurosurgical tools. The peripheral vascular segment offers solutions for peripheral embolization and peripheral thrombectomy. These devices are designed to improve clinical outcomes, reduce procedural times and enhance patient safety, contributing to overall healthcare cost savings.
The company's innovations are supported by a strong commitment to clinical research. Notable achievements include the recent STRIKE-PE study results, which demonstrated the safety and efficacy of Penumbra's Indigo® Aspiration System with Lightning™ technology for treating pulmonary embolism (PE). This computer-assisted vacuum thrombectomy (CAVT) system significantly improved clinical and functional outcomes, such as reduced right heart strain and enhanced patient mobility.
Penumbra's financial performance reflects its robust market presence. For the third quarter of 2023, the company reported revenues of $270.9 million, a 26.8% increase compared to the previous year. The U.S. market accounted for 72% of this revenue, driven by strong sales of thrombectomy products. Gross profits rose to $177.7 million, highlighting the company's ability to leverage its product mix and production efficiencies.
Looking ahead, Penumbra remains focused on expanding its product portfolio and geographic presence. Recent milestones include the launch of Lightning Flash™ 2.0, an advanced CAVT system designed for faster thrombus removal with minimal blood loss. The company also started enrolling patients in the STORM-PE trial, a groundbreaking study comparing CAVT to standard anticoagulation therapy for PE treatment.
Penumbra's strategic vision includes continuous innovation, strengthening partnerships, and expanding its footprint in existing and new markets. The company supports healthcare providers in over 100 countries, ensuring a broad impact on global health outcomes through its cutting-edge medical technologies.
Penumbra (NYSE: PEN) has announced its participation in the upcoming Piper Sandler 36th Annual Healthcare Conference. The company's management team will present on Wednesday, December 4, 2024, at 8:00am ET/5:00am PT.
Interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's website. The webcast recording will remain available for a minimum of two weeks after the event.
Penumbra announced new data showing that patients with intermediate-risk pulmonary embolism (PE) treated with their computer assisted vacuum thrombectomy (CAVT) technology experienced better outcomes compared to other treatments. The study, presented at VIVA 2024, analyzed 2,060 adult patients and revealed that CAVT resulted in 25-35% shorter hospital stays, 25-30% higher rates of home discharge, and 2-3 times fewer complications. The technology also demonstrated potential financial benefits, with hospitals potentially seeing up to a 75% gain in profitable contribution margin if 10% more patients are treated with CAVT compared to anticoagulation alone.
Penumbra (NYSE: PEN) reported strong Q3 2024 financial results with total revenue of $301.0 million, up 11.1% year-over-year. U.S. thrombectomy revenue reached $162.1 million, increasing 21.2% compared to Q3 2023, driven by 32% growth in the VTE franchise. The company achieved net income of $29.5 million with a 9.8% margin and adjusted EBITDA of $56.7 million with an 18.8% margin. Gross profit was $200.3 million with a 66.5% margin. The company maintains its 2024 revenue guidance of $1,180-1,200 million and now expects U.S. thrombectomy growth of 24-25% year-over-year.
Penumbra, Inc. (NYSE: PEN), a leading thrombectomy company, has completed enrollment for its THUNDER clinical study evaluating the safety and efficacy of its latest computer assisted vacuum thrombectomy (CAVT™) technology for acute ischemic stroke patients. The study focuses on the Penumbra System™ with Thunderbolt™ Aspiration Tubing for removing blood clots in the brain.
The Thunderbolt technology uses an advanced CAVT software algorithm to generate modulated aspiration, aiming to reduce friction and facilitate faster, more complete clot removal. The THUNDER study (NCT05437055) is a multi-center, single-arm study involving patients with acute ischemic stroke due to intracranial large vessel occlusion (LVO) eligible for mechanical thrombectomy. The primary efficacy endpoint is the revascularization of the occluded target vessel immediately post-procedure.
The Get Out the Clot campaign has been launched by leading medical societies to improve patient care for venous thromboembolism (VTE). This collaborative initiative aims to identify gaps in care, standardize treatment, and expand access to innovative solutions for blood clot conditions. VTE affects up to 900,000 Americans annually, causing approximately 100,000 deaths and up to $10 billion in associated costs.
The campaign highlights the importance of standardized care paths and multidisciplinary approaches, such as VTE or PE response teams (PERTs), to improve diagnosis and treatment. It also emphasizes the need for awareness of newer treatments like computer-assisted vacuum thrombectomy and mechanical thrombectomy, which can quickly remove blood clots and improve patient outcomes.
The initiative is supported by organizations including the International Society on Thrombosis and Haemostasis (ISTH), National Blood Clot Alliance (NBCA), Penumbra, Inc. (NYSE: PEN), The PERT Consortium™, and the Society for Vascular Medicine (SVM).
Penumbra, Inc. (NYSE: PEN) has announced that it will release its financial results for the third quarter of 2024 after the market closes on Wednesday, October 30, 2024. The company will host a conference call to discuss these results at 4:30 PM Eastern Time on the same day.
Interested parties can access the conference call by dialing (888) 596-4144 with the conference ID: 5872954. Alternatively, a webcast of the call will be available on the 'Events and Presentations' section of Penumbra's website under the 'Investors' tab. The webcast will remain accessible on the company's website for at least two weeks following the call.
Penumbra, Inc. (NYSE: PEN) has received CE Mark approval in Europe for its latest computer assisted vacuum thrombectomy (CAVT) technologies – Lightning Flash™ 2.0 and Lightning Bolt™ 7. These advanced systems are designed to quickly restore blood flow by efficiently removing blood clots.
Lightning Flash 2.0, the most advanced thrombectomy system for venous and pulmonary thrombus in Europe, features dual clot detection algorithms and MaxID hypotube technology. Lightning Bolt 7, the most powerful arterial thrombectomy system, introduces modulated aspiration for rapid removal of large, fibrous blood clots in arteries.
These innovations aim to improve patient outcomes by enabling quicker procedures and more efficient clot removal while maintaining a high level of safety.
Penumbra Inc (NYSE: PEN) has announced its participation in the upcoming Baird Global Healthcare Conference. The company's management team is scheduled to present on Tuesday, September 10, 2024, at 9:05 AM ET / 6:05 AM PT. Investors and interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's official website.
The webcast will remain available on the company's website for at least two weeks following the event, providing an opportunity for those unable to attend the live presentation to review the content. This conference participation highlights Penumbra's commitment to engaging with the investment community and sharing insights about their healthcare innovations.
Penumbra, Inc. (NYSE: PEN) has announced its participation in the upcoming Wells Fargo Healthcare Conference. The company's management team is scheduled to present on Wednesday, September 4, 2024, at 2:15pm ET/11:15am PT. Interested parties can access a webcast of the presentation through the 'Events and Presentations' section under the 'Investors' tab on Penumbra's official website.
The webcast will remain available on the company's website for a minimum of two weeks following the event. This presentation provides an opportunity for investors and analysts to gain insights into Penumbra's current operations and future strategies within the healthcare sector.
Penumbra, Inc. (NYSE: PEN), a leading thrombectomy company, has announced a $200 million share repurchase authorization approved by its Board of Directors on August 5, 2024. The authorization, valid until July 31, 2025, allows Penumbra to repurchase its common stock through various methods. As part of this initiative, Penumbra has entered into a $100 million accelerated share repurchase agreement (ASR) with JPMorgan Chase Bank on August 12, 2024.
Under the ASR, Penumbra will make an initial payment of $100 million and receive approximately 474,000 shares of its common stock on August 13, 2024. The final number of shares repurchased will be determined based on the average daily volume-weighted average prices during the ASR term. The ASR is expected to be completed in the third quarter of 2024, funded by Penumbra's cash on hand.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
What does Penumbra, Inc. specialize in?
What are Penumbra's key product categories?
How does Penumbra's technology improve patient outcomes?
What recent clinical study results have Penumbra announced?
What financial performance did Penumbra report for Q3 2023?
How is Penumbra expanding its product portfolio?
What is the focus of the STORM-PE trial?
Which regions contribute to Penumbra's revenue?
What are Penumbra's future growth strategies?
Where can more information about Penumbra be found?
